COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,788 Articles (22,523 medRxiv, 8,265 bioRxiv)

Most recent first Previous |  Page 1520: Articles 15191-15200  | Next

Is WHO International Standard for Anti-SARS-CoV-2 Immunoglobulin Clinically Useful?
Lukaszuk, K., Kiewisz, J., Rozanska, K., Podolak, A., Jakiel, G., Woclawek-Potocka, I., Lukaszuk, A., Rabalski, L.
10.1101/2021.04.29.21256246 — Posted: 2021-05-02
Rapid implementation of cross-sectional study: Post-acute sequelae of SARS-CoV-2 (PASC) in a racially and ethnically diverse sample in Illinois
Mermelstein, R. J., Aiyer, M., Canfield, C., Chestek, D., Cook, J. A., Del Rios, M., Diviak, K. R., Ellison, A. M., Gordon, H. S., Illendula, S. D., Kandula, M., Klein, J. D., Larimer, K., Lash, J., Lin, J., Loeb, J. A., Lynch, T. J., Musick, H., Novak, R. M., Prendergast, H. M., Krishnan, J. A.
10.1101/2021.04.29.21256304 — Posted: 2021-05-02
COVID-19 and pregnancy: An umbrella review of clinical presentation, vertical transmission, and maternal and perinatal outcomes
Ciapponi, A., Bardach, A., Comande, D., Berrueta, M., Argento, F. J., Rodriguez Cairoli, F., Zamora, N., Santa Maria, V., Xiong, X., Zaraa, S., Mazzoni, A., Buekens, P.
10.1101/2021.04.29.21256327 — Posted: 2021-05-02
Transition in Learning Approach for Undergraduate Medical Students of Bangladesh in Covid 19 Pandemic: A Situation Analysis
Jeenia, F. T., Tanin, M. J. U., Ferdoush, J., Johora, F., Hoque, A., Abbasy, A. A., Sadia, H., Urmi, R., Moitra, P., Sarah, Q. S., Ata, M., Parveen, K.
10.1101/2021.04.29.21256358 — Posted: 2021-05-02
The comparison of vaccine hesitancy of COVID-19 vaccination in China and the United States
Liu, T., He, Z., Huang, J., Yan, N., Chen, Q., Huang, F., Zhang, Y., Akinwunmi, O. M., Akinwunmi, B. O., Zhang, C. J. P., Wu, Y., Ming, W.-k.
10.1101/2021.04.29.21256317 — Posted: 2021-05-02
Quantifying COVID-19 vaccination hesitancy during early vaccination rollout in Canada
Tang, X., Gelband, H., Nagelkerke, N., Bogoch, I., Brown, P. E., Morawski, E., Lam, T., Reid, A., Jha, P., Action to beat coronavirus/Action pour battre le coronavirus (Ab-C) Study Investigators
10.1101/2021.04.29.21256333 — Posted: 2021-05-02
Seroprevalence of SARS-CoV-2 antibodies in broadcast media workers
Martins-Filho, P. R., da Silva, D. N., dos Santos, D. M., Rezende, M. S., Silva, J. P. R., da Silva Neto, J. B., Schimieguel, D. M., Quintans-Junior, L. J., Quintans, J. d. S. S., Nunes, P. S., de Sousa Araujo, A. A.
10.1101/2021.04.29.21256360 — Posted: 2021-05-02
Aspirin and NSAID use and the risk of COVID-19
Drew, D. A., Guo, C.-G., Lee, K., Nguyen, L., Joshi, A. D., Lo, C.-H., Ma, W., Mehta, R. S., Kwon, S., Astley, C. M., Song, M., Davies, R., Capdevila, J., Ni Lochlainn, M. M., Sudre, C., Graham, M. S., Varsavsky, T., Gomez, M. F., Kennedy, B., Fitipaldi, H., Wolf, J., Spector, T., Ourselin, S., Steves, C., Chan, A. T.
10.1101/2021.04.28.21256261 — Posted: 2021-05-02
SARS-CoV-2 antibodies remain detectable 12 months after infection and antibody magnitude is associated with age and COVID-19 severity
Laing, E., Epsi, N. J., Richard, S. A., Samuels, E. C., Wang, W., Vassell, R., Ewing, D. F., Herrup, R., Sterling, S. L., Lindholm, D. A., Millar, E. V., Maves, R. C., Larson, D. T., Colombo, R. E., Chi, S., Madar, C. S., Lalani, T., Ganesan, A., Fries, A., Colombo, C. J., Mende, K., Simons, M. P., Schully, K. L., Weiss, C. D., Tribble, D. R., Agan, B. K., Pollett, S. D., Broder, C. C., Burgess, T. H.
10.1101/2021.04.27.21256207 — Posted: 2021-05-02
Evidence for the utility of cfDNA plasma concentrations to predict disease severity in COVID-19
Hoeter, K., Neuberger, E., Fischer, S., Herbst, M., Juskeviciute, E., Rossmann, H., Sprinzl, M. F., Simon, P., Bodenstein, M., Schäfer, M. K. E.
10.1101/2021.04.29.21256291 — Posted: 2021-05-02

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).